| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 109,833 | 44,298 | ||
| Receivables from collaborative partners | 75,685 | 21,418 | ||
| Short-term investments | 139,123 | 221,412 | ||
| Prepaid expenses and other current assets | 6,009 | 4,778 | ||
| Total current assets | 330,650 | 291,906 | ||
| Property and equipment, net | 1,500 | 1,628 | ||
| Operating lease right-of-use assets | 12,994 | 13,464 | ||
| Long-term investments | 7,698 | 27,996 | ||
| Other long-term assets | 256 | 256 | ||
| Total assets | 353,098 | 335,250 | ||
| Accounts payable | 2,893 | 3,329 | ||
| Accrued expenses | 33,171 | 30,197 | ||
| Current portion of operating lease liability | 2,040 | 2,001 | ||
| Total current liabilities | 38,104 | 35,527 | ||
| Liability related to sale of future royalties | 331,844 | 331,361 | ||
| Operating lease liability, net of current portion | 12,566 | 13,095 | ||
| Common stock, 0.001 par value, 500,000 shares authorized, 27,575 shares and 30,473 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 28 | 28 | ||
| Additional paid in capital | 792,682 | 792,531 | ||
| Accumulated other comprehensive gain | 47 | -6 | ||
| Accumulated deficit | -822,173 | -837,286 | ||
| Total stockholders (deficit) equity | -29,416 | -44,733 | ||
| Total liabilities and stockholders (deficit) equity | 353,098 | 335,250 | ||
ANAPTYSBIO, INC (ANAB)
ANAPTYSBIO, INC (ANAB)